Significantly higher serum levels of sCD163 were observed in patients with malignant tumors compared to patients with benign tumors, 747.4 pg/mL (339.2–2386.7 pg/mL) versus 674.3 pg/mL (303.3–1538.5 pg/mL) (p = 0.044). This evidence concerns the gene CD163 and cancer.